

References

I-29

1. Krystexxa® (pegloticase) for intravenous infusion [package insert]. Horizon Therapeutics USA, Inc. Lake Forest, IL. Revised 03/2021.
2. Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE. Frequency, distribution, and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. *Arthritis Res Ther*. 2017;19:191.
3. Cunha RN, Aguiar R, Farinha F. Impact of pegloticase on patient outcomes in refractory gout: Current perspectives. *Rheumatology: Research & Reviews*. 2018;10:141-149.
4. Schlesinger N, Edwards NL, Yeo AE, et. al. Development of a multivariable improvement measure for gout. *Arthritis Research & Therapy*. 2020;22(1):1-10.
5. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Pegloticase.
6. Micromedex DrugDex Compendium®. 2022. Pegloticase (Krystexxa).
7. Pillinger M, Fields T, Yeo A, Lipsky P. Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase. *Journal of Rheumatology*. 2020;47(4):605-12
8. Pegloticase In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 15, 2014.
9. American College of Rheumatology. 2020 American College of Rheumatology Guidelines for the Management of Gout. *Arthritis Care & Research*. 2020;72(6):744-60.